StockNews.com lowered shares of Acacia Research (NASDAQ:ACTG – Free Report) from a hold rating to a sell rating in a research report released on Wednesday morning.
Acacia Research Trading Up 0.9 %
NASDAQ:ACTG opened at $4.37 on Wednesday. The company has a market capitalization of $425.50 million, a PE ratio of 8.25 and a beta of 0.52. Acacia Research has a 52-week low of $3.66 and a 52-week high of $5.74. The stock’s 50 day moving average price is $4.44 and its 200 day moving average price is $4.70. The company has a quick ratio of 15.95, a current ratio of 16.39 and a debt-to-equity ratio of 0.12.
Insiders Place Their Bets
In other Acacia Research news, Director Isaac T. Kohlberg sold 15,000 shares of Acacia Research stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $4.57, for a total transaction of $68,550.00. Following the transaction, the director now owns 69,274 shares of the company’s stock, valued at $316,582.18. The trade was a 17.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.65% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
About Acacia Research
Acacia is a publicly traded (Nasdaq: ACTG) company that is focused on acquiring and operating businesses across the industrial, energy and technology sectors where it believes it can leverage its expertise, significant capital base, and deep industry relationships to drive value. Acacia evaluates opportunities based on the attractiveness of the underlying cash flows, without regard to a specific investment horizon.
Featured Articles
- Five stocks we like better than Acacia Research
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- P/E Ratio Calculation: How to Assess Stocks
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
- The 3 Best Retail Stocks to Shop for in August
- Vertex’s Pain Drug: Big Pharma’s Next Major Success?
Receive News & Ratings for Acacia Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acacia Research and related companies with MarketBeat.com's FREE daily email newsletter.